© The Author 2006. Published by Oxford University Press.
EDITORIAL |
Idiotype Vaccination in Follicular Lymphoma: Knocking on the Doorway to Cure
Correspondence to: Dan L. Longo, MD, National Institute on Aging, National Institutes of Health, Intramural Research Program, Rm. 1E07, 5600 Nathan Shock Dr., Baltimore, MD 21224-6825 (e-mail: longod@grc.nia.nih.gov).
| The first 150 words of the full text of this article appear below. |
Follicular lymphoma is a tempting therapeutic target. Happily for both patients and physicians, the disease often responds to therapy. A wide range of treatments produce tumor regressions, including single-agent and multiagent chemotherapy; localized and targeted radiation therapy; cytokines such as interferon-
; monoclonal antibodies directed at various cell surface molecules, such as immunoglobulin and CD20; and targeted therapies that interfere with cell functions, such as antisense RNA to bcl-2 and the proteosome inhibitor bortezomib. The various combinations of these modalities are also effective at causing tumor regressions. Indeed, some combinations of these agents (for example, cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab [R-CHOP]) can produce objective responses in nearly 100% of patients (1).
The history of oncology has taught us that when a tumor is responsive to treatment, particularly to many kinds of treatment, by combining active weapons we usually find a way to cure at least a
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Bendandi Aiming at a Curative Strategy for Follicular Lymphoma CA Cancer J Clin, September 1, 2008; 58(5): 305 - 317. [Abstract] [Full Text] [PDF]
|
|